Diabetes, obesity & metabolism · 2026
Oleanolic Acid-Enriched Olive Oil Attenuates Kidney Function Decline in Patients With Type 2 Diabetes: Results From the OLTRAD Randomised Controlled Trial.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
García-González Aída, Matamoros-Domínguez Alejandro, Espinosa-Cabello Juan Manuel, Pérez-Muñoz Gisela, Aranda Manuel Jesús León, Roque-Cuellar María Del Carmen, García-Rey Silvia, Jiménez-Sánchez Andrés, Martínez-Ortega Antonio Jesús, Mangas-Cruz Miguel Ángel, Cerrillo Isabel, Perona Javier S, García-Luna Pedro Pablo, Yubero-Serrano Elena María, Castellano José María
Аннотация
AIMS: Chronic kidney disease (CKD) is a major complication of type 2 diabetes mellitus (T2DM), driven in part by oxidative stress and the accumulation of advanced glycation end products (AGEs). Oleanolic acid (OA), a natural triterpene present in olive-derived matrices, may modulate AGE metabolism. In this prespecified, exploratory secondary analysis of the OLTRAD trial, we evaluated whether long-term intake of OA-enriched olive oil attenuates kidney function decline in patients with T2DM.
METHODS: In the OLTRAD randomised controlled trial, 97 patients with T2DM were assigned to consume OA-enriched olive oil (600 mg OA/kg) or control olive oil for 12 months, alongside standard therapy. Kidney outcomes included estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (uACR). Circulating AGEs (methylglyoxal [MG], carboxymethyllysine [CML]), enzymes involved in AGE metabolism (aldose reductase [AR], glyoxalase-I [GloxI]), and oxidative stress markers (ROS and MDA) were assessed.
RESULTS: OA-enriched olive oil attenuated eGFR decline relative to control, an effect restricted to participants with mildly impaired eGFR at baseline (60-90 mL/min/1.73 m2; time × group interaction p = 0.010), with no significant interaction among participants with normal baseline eGFR. OA-enriched oil also prevented the rise in uACR observed with control oil. Mechanistically, OA reduced AR concentration and increased GloxI activity, resulting in lower circulating MG, whereas CML remained unchanged. OA-enriched oil further reduced ROS and MDA levels, while MDA increased with control oil.
CONCLUSIONS: In this exploratory, hypothesis-generating secondary analysis, long-term consumption of OA-enriched olive oil was associated with attenuated kidney function decline in patients with T2DM, an effect limited to those with baseline mildly impaired eGFR. These changes were associated with modulation of AGE-related pathways and reduced oxidative stress. As the trial was powered for glycemic control rather than renal outcomes, larger, adequately powered studies are needed to confirm these findings before their clinical relevance can be established.
TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT06030544; https://clinicaltrials.gov/study/NCT06030544.
METHODS: In the OLTRAD randomised controlled trial, 97 patients with T2DM were assigned to consume OA-enriched olive oil (600 mg OA/kg) or control olive oil for 12 months, alongside standard therapy. Kidney outcomes included estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (uACR). Circulating AGEs (methylglyoxal [MG], carboxymethyllysine [CML]), enzymes involved in AGE metabolism (aldose reductase [AR], glyoxalase-I [GloxI]), and oxidative stress markers (ROS and MDA) were assessed.
RESULTS: OA-enriched olive oil attenuated eGFR decline relative to control, an effect restricted to participants with mildly impaired eGFR at baseline (60-90 mL/min/1.73 m2; time × group interaction p = 0.010), with no significant interaction among participants with normal baseline eGFR. OA-enriched oil also prevented the rise in uACR observed with control oil. Mechanistically, OA reduced AR concentration and increased GloxI activity, resulting in lower circulating MG, whereas CML remained unchanged. OA-enriched oil further reduced ROS and MDA levels, while MDA increased with control oil.
CONCLUSIONS: In this exploratory, hypothesis-generating secondary analysis, long-term consumption of OA-enriched olive oil was associated with attenuated kidney function decline in patients with T2DM, an effect limited to those with baseline mildly impaired eGFR. These changes were associated with modulation of AGE-related pathways and reduced oxidative stress. As the trial was powered for glycemic control rather than renal outcomes, larger, adequately powered studies are needed to confirm these findings before their clinical relevance can be established.
TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT06030544; https://clinicaltrials.gov/study/NCT06030544.